Economics of the Pharmaceutical SectorModule description #70153 / Version 3
- 6 CP
- Portfolio examination
- Graded
- Winter semester
- German
This module description is not valid in the current semester (Winter semester 2026/27).
| Module / Version | #70153 / #3 |
|---|---|
| Validity | SS 2016 – Summer semester 2020 |
| Available language(s) | German |
| Credit points | 6 |
| Person responsible for the module | Häussler, Bertram |
| Grading | Graded |
| Exam format | Portfolio examination |
| Language(s) of instruction | German |
Affiliation
| Faculty | Fakultät VII |
|---|---|
| Institute | Institut für Volkswirtschaftslehre und Wirtschaftsrecht |
| Academic chair | 37311300 FG Ökonomie des öffentlichen Sektors, insbesondere Gesundheitsökonomie |
Contact
| Office | H 80 |
|---|---|
| Contact person | Busse, Reinhard |
| E-mail address | mig@tu-berlin.de |
| Website | https://www.tu.berlin/mig/ |
Learning outcomes
Pharmaceuticals (drugs) are – at least in European Health Systems – often regarded as public goods. Therefore, the provision and usage of pharmaceuticals are uncoupled from the patients’ willingness to pay.
As a consequence, the realization of a steady stream of innovative medicinal products that often allow totally new ways to handle diseases, requires some form of market regulation. A distinctive feature of this market regulation (compared to the regulation of other network industries) is the fact that the national regulatory authorities have to regulate globally operating firms.
One of the most important regulatory measure that is currently being used is patent law. Patents create temporary monopolies. The idea is to establish sufficient economic incentives for pharmaceutical firms to invest in Research and Development (R&D): On the one hand, R&D in the pharmaceutical sector is a highly risky investment and requires substantial financial commitment, on the other hand – at least in many cases – imitation of successful innovations is quite easy. Thus, patents are necessary to allow innovators to profit from their investment previously made.
However, monopoly structures are welfare reducing through higher prices. Therefore, all industrialised countries have set up further regulatory mechanisms to cut or at least limit prices for drugs and expenses of the health insurance sector – and almost all countries have introduced different mechanims. Accordingly, a complex web of national regulatory systems has evolved that results in a permanent conflict situation between firms and regulatory authorities and between countries.
Despite these difficult legal conditions, the pharmaceutical industry is one of the most R&D-intense sectors and one of the most important knowledge-creating sectors. (Resulting, amongst others, in an international competition for the location of pharmaceutical firms.)
The intention of this module is first to understand competition and regulation in the pharmaceutical sector, which is in many points an extreme example in context of the industrialeconomic theory. Furthermore, solution will be discussed to optimize the different goals in the market. Second, alternative settings, regulation as well as competition policy, that aim to resolve the conflict between incentives to innovate and prevention of super-normal profits are discussed and assessed. The module relies on the basic knowledge of Industrial Economics and carve out its distinctive features in comparison to other markets.
As a consequence, the realization of a steady stream of innovative medicinal products that often allow totally new ways to handle diseases, requires some form of market regulation. A distinctive feature of this market regulation (compared to the regulation of other network industries) is the fact that the national regulatory authorities have to regulate globally operating firms.
One of the most important regulatory measure that is currently being used is patent law. Patents create temporary monopolies. The idea is to establish sufficient economic incentives for pharmaceutical firms to invest in Research and Development (R&D): On the one hand, R&D in the pharmaceutical sector is a highly risky investment and requires substantial financial commitment, on the other hand – at least in many cases – imitation of successful innovations is quite easy. Thus, patents are necessary to allow innovators to profit from their investment previously made.
However, monopoly structures are welfare reducing through higher prices. Therefore, all industrialised countries have set up further regulatory mechanisms to cut or at least limit prices for drugs and expenses of the health insurance sector – and almost all countries have introduced different mechanims. Accordingly, a complex web of national regulatory systems has evolved that results in a permanent conflict situation between firms and regulatory authorities and between countries.
Despite these difficult legal conditions, the pharmaceutical industry is one of the most R&D-intense sectors and one of the most important knowledge-creating sectors. (Resulting, amongst others, in an international competition for the location of pharmaceutical firms.)
The intention of this module is first to understand competition and regulation in the pharmaceutical sector, which is in many points an extreme example in context of the industrialeconomic theory. Furthermore, solution will be discussed to optimize the different goals in the market. Second, alternative settings, regulation as well as competition policy, that aim to resolve the conflict between incentives to innovate and prevention of super-normal profits are discussed and assessed. The module relies on the basic knowledge of Industrial Economics and carve out its distinctive features in comparison to other markets.
Content
1. Market structure and economic relevance of the pharmaceutical industry
2. Expectation of society
3. Fundamental requirements of supply (technology) and demand (price elasticity)
4. Business model of the pharmaceutical industry
5. Market structure: Access and concentration
6. Characteristics of patents for pharmaceuticals
7. Regulation of the pharmaceutical industry in Germany and abroad
8. Methods for the clinical and economic assessment of drugs
9. Research processes
10. Product strategies
11. Pricing
12. Marketing and distribution
13. Cooperation and M&A
14. Outlook: Where does the industry go?
2. Expectation of society
3. Fundamental requirements of supply (technology) and demand (price elasticity)
4. Business model of the pharmaceutical industry
5. Market structure: Access and concentration
6. Characteristics of patents for pharmaceuticals
7. Regulation of the pharmaceutical industry in Germany and abroad
8. Methods for the clinical and economic assessment of drugs
9. Research processes
10. Product strategies
11. Pricing
12. Marketing and distribution
13. Cooperation and M&A
14. Outlook: Where does the industry go?
Module components
Compulsory area
The following courses are mandatory for this module:
| Courses | Type | Number | Frequency | Language | Hours per week | Course catalog |
|---|---|---|---|---|---|---|
| Ökonomik der pharmazeutischen Industrie | Integrated course | 71 150 L 1628 | Winter semester | [de] | 4 | ISIS |
Workload and credit points
Ökonomik der pharmazeutischen Industrie (Integrated course)
| Workload description | Multiplier | Hours | Total |
|---|---|---|---|
| Hausaufgaben und Nachbereitung | 15 | 6 h | 90 h |
| Präsenzzeit | 15 | 4 h | 60 h |
| Prüfungsvorbereitung | 1 | 30 h | 30 h |
| 180 h | |||
The workload of the module adds up to 180 hours. The module therefore comprises 6 credit points.
Description of teaching and learning methods
Integrierte Veranstaltung (IV)
Requirements for participation and examination
Desirable prerequisites for participation in the courses:
Grundkenntnisse des Gesundheitssystems in Deutschland
Mandatory requirements for the module examination registration:
The examination requirements could not be retrieved.
Completion of the module
| Grading | Graded |
|---|---|
| Exam format | Portfolio examination |
| Language | German |
Test elements
| Name | Points/Weight | Category | Duration/Extent |
|---|---|---|---|
| Homework | 50 | ||
| Klausur | 50 |
Exam description
Die Portfolioprüfung besteht aus den folgenden Elementen, in denen in der Summe maximal 100 Punkte erreicht werden können. Die Benotung erfolgt nach dem gemeinsamen Notenschlüssel der Fakultät VII (Beschluss des Fakultätsrates vom 28.05.2014 - FKR VII-4/8-28.05.2014).
Duration of the module
The following number of semesters is estimated for taking and completing the module: 1 semester(s).
This module can be started in the following semesters: Winter semester.
Maximum number of participants
This module is not limited to a number of students.
Registration procedures
Zur Teilnahme am Modul ist keine Anmeldung erforderlich.
Recommended reading, lecture notes
Lecture notes
unavailable
Electronic lecture notes
available – www.haeussler-tu-berlin.de
Recommended literature
- Wird veröffentlicht auf www.haeussler-tu-berlin.de
Assigned programs
This module version is used in the following programs:
| Program / program version | Semester(s) | Curriculum component |
|---|---|---|
| Industrial Economics StuPO 2018 | SS 2020 | Compulsory Elective Modules › Field Courses › Field Courses |
| Industrial Engineering and Management Industrial Engineering and Management (M. Sc.) - StuPO 2015 | SS 2020 | Wirtschaftswissenschaften/Economic Sciences › Volkswirtschaftslehre/Economics (Wahlpflicht/Compulsory-Elective) › Health Economics |
Miscellaneous
Not specified